George Zorich has been in pharmaceutical fields for over 40 years, including Big Pharma, Biotech, Generics, Distribution companies and Start-ups.
Most recently, Mr. Zorich was on the board of Custopharm which sold to Hikma in 2022 and is currently on the board of Nevakar, Inc. Prior to that he was CEO of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich’s ataxia using DNA based therapies, which was sold to PTC Therapeutics. He was also the president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products, leading to the sale to Mylan Pharmaceuticals for $550MM in late 2010. Before that, Mr. Zorich was president of Sabex-USA leading to its sale to Sandoz for $480MM in 2004, where he then headed up the Sandoz US injectable business.
Before that, he was president of GIV, which at that time was the largest distributor of vaccines to physician offices, leading to the sale to Henry Schein, the multibillion-dollar distributor. Mr. Zorich has also held executive positions at Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories and began at Eli Lilly and Company.
Mr. Zorich received his pharmacy degree from the University of Wisconsin.